| Metabolite quantitation: detector technology and MIST implications. | |
| | |
MedLine Citation:
|
PMID: 21083141 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
HPLC detector technology has advanced dramatically over the past 20 years, with a range of highly sensitive and specific detectors becoming available. What is still missing from the bioanalyst's armoury, however, is a highly sensitive detector that gives an equimolar response independent of the compound. This would allow for quantification of compounds without the requirement for a synthetic standard or a radiolabeled analogue. In particular, such a detector applied to metabolism studies would establish the relative significance of the various metabolic routes. The recently issued US FDA guidelines on metabolites in safety testing (MIST) focus on the relative quantitation of human metabolites being obtained as soon as feasible in the drug-development process. In this article, current detector technology is reviewed with respect to its potential for quantitation without authentic standards or a radiolabel and put in the context of the MIST guidelines. The potential for future developments are explored. |
| | |
Authors:
|
Pat Wright; Zhuang Miao; Barclay Shilliday |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Bioanalysis Volume: 1 ISSN: 1757-6199 ISO Abbreviation: Bioanalysis Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2010-11-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101512484 Medline TA: Bioanalysis Country: England |
Other Details:
|
Languages: eng Pagination: 831-45 Citation Subset: IM |
Affiliation:
|
Pfizer Global Research and Development, Sandwich Laboratories, Kent, CT13 9NJ, UK. pat.wright@pfizer.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Biotechnological synthesis of drug metabolites using human cytochrome P450 isozymes heterologously e...
Next Document: Recent progress in selected reaction monitoring MS-driven plasma protein biomarker analysis.